Telix Pharmaceuticals LtdTelix Pharmaceuticals Ltd - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

The ESG rating includes seventeen United Nations SDGs including: 'Gender Equality', 'Sustainable Cities & Communities' and 'Peace, Justice & Strong Institutions'. If you work at Telix Pharmaceuticals Ltd and you would like to use your Sustainability rating, please get in touch. The article includes a Q&A section on Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.7; made up of an environmental score of 4.0, social score of 8.0 and governance score of 8.0.

SDG Transparency Score for Telix Pharmaceuticals Ltd 
Low
0 - 3

6.7

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2024-05-01
What drives the score for Telix Pharmaceuticals Ltd 
4.0

Environmental

8.0

Social

8.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Caladrius Biosciences Inc
8.0
High
1Can Fite Biopharma Ltd
8.0
High
314Trulieve Cannabis Corp
6.8
High
314Vicore Pharma Holding AB
6.8
High
337Telix Pharmaceuticals Ltd
6.7
High
337Calyxt Inc
6.7
High
337CanSino Biologics Inc
6.7
High
.........
1970Zyden Gentec Ltd
0.0
Low
1970iNtRON Biotechnology Inc
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Telix Pharmaceuticals Ltd have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd report the average age of the workforce?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose cybersecurity risks?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd offer flexible work?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd conduct supply chain audits?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose water use targets?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Telix Pharmaceuticals Ltd have a product recall in the last two years?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose incidents of discrimination?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Telix Pharmaceuticals Ltd issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose parental leave metrics?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Telix Pharmaceuticals Ltd involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose its waste policy?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd report according to TCFD requirements?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose energy use targets?

LockedSign up for free to unlock

Does Telix Pharmaceuticals Ltd disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Telix Pharmaceuticals Ltd have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Telix Pharmaceuticals Ltd
These potential risks are based on the size, segment and geographies of the company.

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Sorry!

Failed to process!